It was music to investors' ears the last time Jazz Pharmaceuticals (NASDAQ: JAZZ) announced its quarterly results in May. Revenue was up 14% year over year with adjusted earnings jumping 17% higher.
Jazz announced its second-quarter results after the market closed on Tuesday. Here are the highlights from the drugmaker's quarterly update.
Image source: Getty Images.
By the numbers
Jazz reported revenue in the second quarter of $534 million. This reflected a 7% increase from the prior-year period revenue total of $500.5 million. The consensus among Wall Street analysts projected Q2 revenue of $508.62 million.
The company reported net income of $261.9 million, or $4.56 per share, on a generally accepted accounting principles (GAAP) basis. In the prior-year period, Jazz posted GAAP net income of $92.3 million, or $1.50 per share.
Adjusted net income in the second quarter came in at $232.5 million, or $4.05 per share. This was a solid improvement over Jazz's result in the same quarter in 2018 when the company announced adjusted earnings of $214.6 million, or $3.49 per share. It was also much better than the consensus analysts' adjusted earnings estimate of $3.57 per share.
Behind the numbers
The big story for Jazz Pharmaceuticals in the second quarter was continued momentum for Xyrem. Sales for the sleep disorder drug jumped 16% year over year to $413.2 million. Jazz also enjoyed solid growth for hepatic veno-occlusive disease drug Defitelio and acute myeloid leukemia (AML) drug Vyxeos.
However, these gains were partially offset by lower sales for blood cancer drug Erwinaze. Sales for Erwinaze plunged 53% year over year in Q2 to $27.6 million. Jazz Pharmaceuticals attributed the steep decline to ongoing quality and supply issues at the manufacturer for the drug.
The company's overall revenue growth was enough to drive earnings higher as well despite increased operating expenses. Jazz also received help from a large income tax benefit in the second quarter of 2019.
Jazz highlighted some other key developments in the second quarter in its update. In June, the Children's Oncology Group presented positive data from a phase 1/2 study evaluating Vyxeos in treating children and young adults with AML at the American Society of Clinical Oncology (ASCO) meeting. Also in June, Japanese regulators approved Defitelio in treating sinusoidal obstruction syndrome/hepatic veno-occlusive disease.
Jazz expects that revenue for full-year 2019 will be between $2.07 billion and $2.15 billion, up from its previous guidance range of $2.05 billion to $2.13 billion. The company anticipates GAAP earnings per share (EPS) of $9.40 to $10.75. Jazz's previous outlook called for GAAP EPS between $6.80 and $8.50. The drugmaker reaffirmed its previous guidance of full-year adjusted non-GAAP EPS between $14.30 and $15.
There are plenty of things for investors to look forward to with Jazz's pipeline. CEO Bruce Cozadd said that the company plans to file for U.S. approval of JZP-258 in treating narcolepsy in the second half of 2019. Jazz also hopes to win approval for Sunosi in Europe later this year. In addition, the company plans to kick off several clinical studies of Vyxeos as well as initiate a pivotal study of JZP-458 in treating acute lymphoblastic leukemia.
This article was originally published on Fool.com